Injectable Drug Delivery Market Forecast to 2033

Technological Advancements in Prefilled Syringes, Injection Pens, and Autoinjectors to Drive Injectable Drug Delivery Market to USD 900 Bn by 2033 at 7% CAGR – Coherent Market Insights

Global Injectable Drug Delivery Market, by Device Type (Prefilled Syringes, Autoinjectors, Pens, Conventional Syringes, Cartridges, Ampoules, Vials, and Others), by Material Type (Glass and Plastic), by Usability (Disposable and Reusable), by Route of Administration (Intravenous, Intramuscular, and Subcutaneous), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at USD 650 Bn in 2026, and is projected to exhibit a CAGR of 7% over the forecast period (2026 – 2033), as highlighted in a new report published by Coherent Market Insights.

Market Driver

The increasing prevalence of chronic diseases, combined with growing demand for convenient self-administration, is a major driver of the global injectable drug delivery market. Long-term conditions such as diabetes, autoimmune disorders, cancer, obesity, and neurological diseases frequently require repeated dosing, encouraging the adoption of prefilled syringes, injection pens, wearable injectors, and autoinjectors. Noncommunicable diseases account for approximately 75% of non-pandemic-related deaths globally, highlighting the substantial need for long-term treatment solutions.

For instance, on July 13, 2026, the U.S. FDA approved Eisai’s LEQEMBI IQLIK subcutaneous autoinjector as an initiation treatment for early Alzheimer’s disease. It is the first approved at-home starting-dose option for an Alzheimer’s treatment, providing a convenient alternative to intravenous administration. The initiation regimen consists of two 250 mg injections administered once weekly, with each injection delivered in approximately 15 seconds. This approval demonstrates the growing transition toward patient-centric, home-based injectable therapies for chronic conditions. (Source: World Health Organization, U.S. Food and Drug Administration, Eisai Media Center)

Market Opportunity

Expansion of Patient-Centric Self-Administration Systems

The growing shift from hospital-based drug administration toward home-based self-injection creates a significant opportunity for the injectable drug delivery industry. Pharmaceutical and device manufacturers can develop wearable injectors, prefilled syringes, autoinjectors, and pen injectors capable of safely delivering biologics, monoclonal antibodies, oncology medicines, diabetes drugs, and weight-management therapies. Large-volume delivery systems are particularly promising, as many biologic formulations exceed the capacity of conventional syringes and require controlled subcutaneous administration.

For instance, in January 2026, Datwyler, LTS Device Technologies, and Stevanato Group announced a collaboration to develop a pre-verified on-body delivery platform for 10 mL and 20 mL cartridges. The system is intended to enable convenient home administration of higher-dose therapies, including monoclonal antibodies and anti-cancer treatments, while accelerating product development and commercialization. This development demonstrates increasing commercial opportunities in large-volume, patient-friendly injectable delivery solutions. (Source: ir.stevanatogroup.com)

Market Trends

Development of Large-Volume and High-Viscosity Autoinjectors

The increasing use of high-dose biologics is driving the development of autoinjectors and prefilled syringes capable of delivering larger volumes and more viscous formulations. In January 2026, BD and Ypsomed expanded their partnership to develop a 5.5 mL BD Neopak XtraFlow glass prefillable syringe compatible with the YpsoMate 5.5 autoinjector. The system is being designed for large-volume subcutaneous self-injections and incorporates a shorter needle and thin-wall cannula technology to improve flow and reduce injection time.

Rising Demand for Prefillable Syringes for Biologics and GLP-1 Therapies

Rapid growth in biologics and injectable GLP-1 therapies is increasing demand for ready-to-use prefillable syringes that support accurate dosing, reduced preparation requirements, and integration with autoinjectors. In January 2026, BD announced a USD 110 million investment to expand U.S. production of BD Neopak glass prefillable syringes and cannulas. The company stated that the investment would support growing demand for biologic and GLP-1 drug delivery, with syringe supply from its expanded Nebraska facility expected to begin in mid-2026.

Advanced Cartridges for Sensitive and Complex Biologics

Drug-containment manufacturers are developing cartridges with improved chemical resistance, controlled silicone levels, and lower extractables and leachables to protect sensitive biological molecules. For instance, in April 2026, SCHOTT Pharma announced the development of cartriQ BioPure, a sterile glass cartridge for monoclonal antibodies, fusion proteins, and other complex biologics. The cartridge will be available in 3 mL and 5 mL formats for integration into injection pens and autoinjectors, thereby supporting reliable self-administration.

To know the latest trends and insights prevalent in the injectable drug delivery market, click the link below:

https://www.coherentmarketinsights.com/market-insight/injectable-drug-delivery-market-2768

Key players in the injectable drug delivery market are adopting strategic collaborations to broaden their service capabilities and accelerate the development and commercialization of advanced drug–device combination products. For instance, in April 2026, Becton, Dickinson and Company entered into a partnership with Suttons Creek to combine BD’s drug-delivery expertise with Suttons Creek’s consulting and device-agnostic testing capabilities. The collaboration is intended to help pharmaceutical and biotechnology companies reduce development risks and bring injectable combination products, including biologics and GLP-1 therapies, to market more efficiently.

Key Takeaways of the Global Injectable Drug Delivery Market

The global injectable drug delivery market is expected to exhibit a CAGR of 7.0% over the forecast period, supported by the introduction of advanced subcutaneous formulations and patient-centric drug-delivery systems by leading pharmaceutical companies. For instance, in May 2026, Roche Pharma India launched Tecentriq SC (atezolizumab) in India, the country’s first subcutaneous immunotherapy for lung cancer. The formulation can be administered in approximately seven minutes, compared with conventional intravenous infusions that may require several hours, improving patient convenience and healthcare-resource utilization.
Key players operating in the global injectable drug delivery market include, Becton, Dickinson and Company, Pfizer Inc., Novo Nordisk A/S, Gerresheimer AG, Carl-Zeiss-Stiftung, Terumo Corporation, Vetter Pharma-Fertigung GmbH & Co. KG, SHL Group, Owen Mumford Limited, Injex Pharma GmbH

Key Development

In January 2026, MGS revealed the launch of the A.i.r. Platform, a customizable autoinjector platform supporting fill volumes from 0.3 mL to 2.25 mL. It offers adjustable injection times, compatibility with different drug viscosities, audible feedback, and patient-specific device configurations.
In January 2026, West Pharmaceutical Services, Inc. announced the global commercial availability of its West Synchrony S1 Prefillable Syringe System. The integrated and verified platform includes 1 mL and 2.25 mL syringe formats for biologics, vaccines, and drug-device combination products. The launch strengthens the availability of ready-to-use injectable delivery systems that can simplify component selection, improve compatibility, reduce development risks, and support the movement of injectable therapies from hospitals to home-based care. (Source: West Pharmaceutical Services, Inc.)
In April 2026, AstraZeneca received U.S. approval for the subcutaneous self-administration of Saphnelo through a once-weekly 120 mg autoinjector, known as the Saphnelo Pen, or a prefilled syringe. (Source: AstraZeneca)